RecruitingNCT07388966
Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia
Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia Using Syde®
Sponsor
SYSNAV
Enrollment
40 participants
Start Date
Feb 6, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The study aims to identify which Syde®-derived digital outcomes are reliable in FGFR3-related Skeletal Dysplasia. This requires to set-up a natural history study to measure limb movements in patients with ACH or HCH.
Eligibility
Min Age: 3 YearsMax Age: 65 Years
Inclusion Criteria8
- Aged 3 years old or older at the time of consent.
- Written informed consent obtained:
- From the parent(s) or legal guardian(s) for participants under 18 years old.
- From participants 18 years old and older.
- Affiliated to, or beneficiary of a social security category
- Able to walk unassisted for at least 10 meters.
- Genetically confirmed diagnosis with one pathogenic variant (ACMG class IV \& V) of achondroplasia or hypochondroplasia.
- Participant (and caregivers for participants under 18 years old) willing and able to comply with all study procedures including: questionnaires, Syde® related procedures
Exclusion Criteria9
- Subjects who have short stature condition other than ACH/HCH.
- Presence of cognitive disorders that limit their understanding of the data collection process (training of device use and 4-week recording periods every 6 months, device return at the end of the study), the implication of the study and consent.
- Presence or history of any concurrent disease or condition that could interfere with study participation, impact pediatric growth, affect motor or balance or gait function (such as neurological, endocrine, infectious, allergic, osteoarthritis, or inflammatory), assessed by the investigator.
- Females who are pregnant, or planning to become pregnant during the study duration.
- Body Mass Index = 35 kg/m2.
- Recent upper and/or lower limbs injury (trauma/fracture or surgery) in the 6 months preceding inclusion.
- Prior limb lengthening surgery or planned or expected to have limb lengthening surgery while enrolled in the study.
- Presence of guided growth hardware (such as 8-plates) or planned orthopedic surgeries during the study.
- Vulnerable patient (guardianship, curatorship or safeguarding of justice), unable to provide informed consent or who is unable to express their consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07388966
Related Trials
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT0684235515 locations
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
NCT067328955 locations
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
NCT074418762 locations
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
NCT0607939818 locations
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
NCT0716927913 locations